Featured Article
Have you missed this November 2024 article that’s been making headlines? GLP-1 receptor agonists (GLP1RAs), including liraglutide and semaglutide, are proving effective beyond their established roles in weight loss and type 2 diabetes management. With anti-inflammatory properties targeting key inflammatory pathways, they offer therapeutic potential for conditions like psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. Dermatologists should also be aware of potential cutaneous adverse effects, including dermal hypersensitivity and “Ozempic Face,” associated with rapid weight loss. Explore the emerging dermatologic applications of GLP1RAs and their impact on patient care.
